Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells

Blood

Volumn 114, Issue 10, 2009, Pages 2197-2206

  Shao, Esther S ^a,b   Lin, Laura ^a   Yao, Yucheng ^a   Boström, Kristina I ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 9; SMAD1 PROTEIN; SMAD2 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN; ACTIVIN RECEPTOR 2; ACVRL1 PROTEIN, HUMAN; BMP4 PROTEIN, HUMAN; GDF2 PROTEIN, HUMAN; GROWTH DIFFERENTIATION FACTOR; PROTEIN SERINE THREONINE KINASE; TGF BETA TYPE I RECEPTOR; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STIMULATION; TUBE; ANIMAL; BIOSYNTHESIS; CATTLE; CELL CULTURE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; TIME;

ACTIVIN RECEPTORS, TYPE II; ANIMALS; BONE MORPHOGENETIC PROTEIN 4; CATTLE; CELLS, CULTURED; ENDOTHELIAL CELLS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GROWTH DIFFERENTIATION FACTORS; HUMANS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349260659     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-01-199166     Document Type: Article

References (45)

1. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A(164/ 165) and PlGF: roles in angiogenesis and arteriogenesis. Trends Cardiovasc Med. 2003;13:169-175.
2. Ozawa CR, Banfi A, Glazer NL, et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest. 2004;113:516-527. (Pubitemid 38542501)
3. Sadick H, Naim R, Gossler U, Hormann K, Riedel F. Angiogenesis in hereditary hemorrhagic telangiectasia: VEGF165 plasma concentration in correlation to the VEGF expression and microvessel density. Int J Mol Med. 2005;15:15-19.
4. Sundberg C, Nagy JA, Brown LF, et al. Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am J Pathol. 2001;158:1145-1160.
5. Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-β1 as well as high ALK1 tissue expression. Haematologica. 2005;90:818-828. (Pubitemid 40897224)
6. Srinivasan S, Hanes MA, Dickens T, et al. A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum Mol Genet. 2003;12: 473-482. (Pubitemid 36305588)
7. Thomas B, Eyries M, Montagne K, et al. Altered endothelial gene expression associated with hereditary haemorrhagic telangiectasia. Eur J Clin Invest. 2007;37:580-588. (Pubitemid 46920194)
8. Urness LD, Sorensen LK, Li DY. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet. 2000;26:328-331.
9. Bostrom K, Zebboudj AF, Yao Y, Lin TS, Torres A. Matrix GLA protein stimulates VEGF expression through increased transforming growth factor-β1 activity in endothelial cells. J Biol Chem. 2004; 279:52904-52913. (Pubitemid 40051789)
10. Breier G, Blum S, Peli J, et al. Transforming growth factor-β and Ras regulate the VEGF/ VEGF-receptor system during tumor angiogenesis. Int J Cancer. 2002;97:142-148. (Pubitemid 34019947)
11. Iglesias-de la Cruz MC, Ziyadeh FN, Isono M, et al. Effects of high glucose and TGF-β1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int. 2002;62:901-913. (Pubitemid 35316719)
12. Pertovaara L, Kaipainen A, Mustonen T, et al. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem. 1994; 269:6271-6274. (Pubitemid 24190991)
13. Renner U, Lohrer P, Schaaf L, et al. Transforming growth factor-β stimulates vascular endothelial growth factor production by folliculostellate pituitary cells. Endocrinology. 2002;143:3759-3765.
14. He C, Chen X. Transcription regulation of the vegf gene by the BMP/Smad pathway in the angioblast of zebrafish embryos. Biochem Biophys Res Commun. 2005;329:324-330.
15. Bobik A. Transforming growth factor-βs and vascular disorders. Arterioscler Thromb Vasc Biol. 2006;26:1712-1720.
16. Attisano L, Carcamo J, Ventura F, Weis FM, Massague J, Wrana JL. Identification of human activin and TGF β type I receptors that form heteromeric kinase complexes with type II receptors. Cell. 1993;75:671-680.
17. Goumans MJ, Valdimarsdottir G, Itoh S, et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFβ/ALK5 signaling. Mol Cell. 2003;12:817-828.
18. Seki T, Hong KH, Oh SP. Nonoverlapping expression patterns of ALK1 and ALK5 reveal distinct roles of each receptor in vascular development. Lab Invest. 2006;86:116-129.
19. Park SO, Lee YJ, Seki T, et al. ALK5- and TGFBR2- independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood. 2008;111:633-642.
20. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood. 2007; 109:1953-1961.
21. Yao Y, Zebboudj AF, Shao E, Perez M, Bostrom K. Regulation of bone morphogenetic protein-4 by matrix GLA protein in vascular endothelial cells involves activin-like kinase receptor 1. J Biol Chem. 2006;281:33921-33930.
22. Yao Y, Zebboudj AF, Torres A, Shao E, Boström K. Activin-like kinase receptor 1 (ALK1) in atherosclerotic lesions and vascular mesenchymal cells. Cardiovasc Res. 2007;74:279-289.
23. Yao Y, Shao ES, Jumabay M, Shahbazian A, Ji S, Boström KI. High-density lipoproteins affect endothelial BMP signaling by modulating expression of the activin-like kinase receptor 1 and 2. Arterioscler Thromb Vasc Biol. 2008;28:2266-2274.
24. Garfinkel A, Tintut Y, Petrasek D, Bostrom K, Demer LL. Pattern formation by vascular mesenchymal cells. Proc Natl Acad Sci U S A. 2004; 101:9247-9250.
25. Yao Y, Nowak S, Yochelis A, Garfinkel A, Boström KI. Matrix GLA protein, an inhibitory morphogen in pulmonary vascular development. J Biol Chem. 2007;282:30131-30142.
26. Lee H, Shi W, Tontonoz P, et al. Role for peroxisome proliferator- activated receptor α in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res. 2000;87:516-521. (Pubitemid 30736746)
27. Zilberberg L, ten Dijke P, Sakai LY, Rifkin DB. A rapid and sensitive bioassay to measure bone morphogenetic protein activity. BMC Cell Biol. 2007;8:41.
28. Lux A, Attisano L, Marchuk DA. Assignment of transforming growth factor β1 and β3 and a third new ligand to the type I receptor ALK-1. J Biol Chem. 1999;274:9984-9992. (Pubitemid 129518279)
29. David L, Mallet C, Keramidas M, et al. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ Res. 2008;102:914-922. (Pubitemid 351591550)
30. Boon RA, Fledderus JO, Volger OL, et al. KLF2 suppresses TGF-β signaling in endothelium through induction of Smad7 and inhibition of AP-1. Arterioscler Thromb Vasc Biol. 2007;27: 532-539.
31. Karlsson G, Liu Y, Larsson J, et al. Gene expression profiling demonstrates that TGF-β1 signals exclusively through receptor complexes involving Alk5 and identifies targets of TGF-β signaling. Physiol Genomics. 2005;21:396-403. (Pubitemid 40898500)
32. Lenato GM, Guanti G. Hereditary haemorrhagic telangiectasia (HHT): genetic and molecular aspects. Curr Pharm Des. 2006;12:1173-1193. (Pubitemid 44096579)
33. Sadick H, Sadick M, Gotte K, et al. Hereditary hemorrhagic telangiectasia: an update on clinical manifestations and diagnostic measures. Wien Klin Wochenschr. 2006;118:72-80.
34. Heinke J, Wehofsits L, Zhou Q, et al. BMPER is an endothelial cell regulator and controls bone morphogenetic protein-4-dependent angiogenesis. Circ Res. 2008;103:804-812.
35. Yao Y, Shahbazian A, Boström KI. Proline and γ-carboxylated glutamate residues in matrix Gla protein are critical for binding of bone morphogenetic protein-4. Circ Res. 2008;102:1065-1074. (Pubitemid 351667860)
36. Oh SP, Seki T, Goss KA, et al. Activin receptorlike kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A. 2000;97:2626-2631. (Pubitemid 30159221)
37. Roman BL, Pham VN, Lawson ND, et al. Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels. Development. 2002; 129:3009-3019.
38. Hirose S, Hosoda Y, Furuya S, Otsuki T, Ikeda E. Expression of vascular endothelial growth factor and its receptors correlates closely with formation of the plexiform lesion in human pulmonary hypertension. Pathol Int. 2000;50:472-479. (Pubitemid 30482392)
39. Scharpfenecker M, van Dinther M, Liu Z, et al. BMP-9 signals via ALK1 and inhibits bFGFinduced endothelial cell proliferation and VEGFstimulated angiogenesis. J Cell Sci. 2007;120: 964-972.
40. Zebboudj AF, Imura M, Bostrom K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem. 2002;277:4388-4394. (Pubitemid 34968705)
41. Laks H, Ardehali A, Grant PW, et al. Modification of the Fontan procedure: superior vena cava to left pulmonary artery connection and inferior vena cava to right pulmonary artery connection with adjustable atrial septal defect. Circulation. 1995; 91:2943-2947.
42. Shah MJ, Rychik J, Fogel MA, Murphy JD, Jacobs ML. Pulmonary AV malformations after superior cavopulmonary connection: resolution after inclusion of hepatic veins in the pulmonary circulation. Ann Thorac Surg. 1997;63:960-963. (Pubitemid 27191644)
43. AboulHosn J, Danon S, Levi D, Castellon Y, Child J, Moore J. Regression of pulmonary arteriovenous malformations after transcatheter reconnection of the pulmonary arteries in patients with unidirectional Fontan. Congenit Heart Dis. 2007; 2:179-184. (Pubitemid 46901508)
44. Miller AF, Harvey SA, Thies RS, Olson MS. Bone morphogenetic protein-9: an autocrine/paracrine cytokine in the liver. J Biol Chem. 2000;275: 17937-17945. (Pubitemid 30414737)
45. Herve P, Lebrec D, Brenot F, et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J. 1998;11:1153-1166. (Pubitemid 28281039)